For the year ending 2025-12-31, KYNB had -$54,306K decrease in cash & cash equivalents over the period. -$4,812K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 183,452 |
| Depreciation | 713 |
| Amortization of finance lease right-of-use assets | 35 |
| Net accretion of premium and discount on investments | 72 |
| Investment income in unconsolidated variable interest entity | 2,485 |
| Gain on divestiture | 52,553 |
| Loss on debt extinguishments | -6,583 |
| Impairment of property and equipment | 2,062 |
| Loss on disposal of property and equipment | 0 |
| Stock-based compensation | 6,576 |
| Dividend received from unconsolidated variable interest entity | 3,947 |
| Accounts receivable, net | 2,543 |
| Inventories | -5,362 |
| Prepaid expenses and other current assets | -54,102 |
| Operating lease right-of-use assets | -808 |
| Other assets | 902 |
| Accounts payable | -27,654 |
| Accrued and other liabilities | -53,497 |
| Operating lease liabilities, current | -568 |
| Deferred revenues | -136,429 |
| Accrued interest expense related to sale of future revenues | 7,990 |
| Accrued interest for finance lease liabilities | 6 |
| Operating lease liabilities, non-current | -202 |
| Other long-term liabilities | 495 |
| Net cash used in operating activities | -4,774 |
| Purchases of property and equipment | 38 |
| Proceeds from divestiture, net of cash transferred | 96,615 |
| Proceeds from sale of property and equipment | 0 |
| Purchases of available-for-sale securities | 61,158 |
| Proceeds from maturities of investments | 0 |
| Net cash provided by investing activities | 35,419 |
| Repayments of senior secured term loan facilities | 75,000 |
| Payment of senior secured term loan facilities pay-off premium and fees | 5,550 |
| Repayments of finance lease liabilities | 10 |
| Cash paid for payroll taxes on restricted stock unit releases | 69 |
| Cash paid to non-controlling interest | 5,353 |
| Payment of issuance cost under atm program | 46 |
| Proceeds from issuance of common stock under employee stock plans | 0 |
| Net cash used in financing activities | -86,028 |
| Effect of exchange rate change on cash and cash equivalents | 1,077 |
| Net decrease in cash and cash equivalents | -54,306 |
| Total cash and cash equivalents at beginning of period | 102,178 |
| Total cash and cash equivalents at end of period | 47,872 |
KYNTRA BIO, INC. (KYNB)
KYNTRA BIO, INC. (KYNB)